Has the time arrived for biomarker-directed therapy in castration-resistant prostate cancer?

JAMA Oncology

Volumn 1, Issue 5, 2015, Pages 577-579

  Taplin, Mary Ellen ^a   Balk, Steven P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADENOCARCINOMA; GENETICS; HUMAN; MALE; METABOLISM; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84989775054     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1457     Document Type: Review

References (11)

1. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer. 2014;21(4): T87-T103.
2. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028-1038.
3. Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer [published online June 4, 2015]. JAMA Oncol. doi:10.1001 /jamaoncol.2015.1341.
4. Nelson PS. Targeting the androgen receptor in prostate cancer-a resilient foe. N Engl J Med. 2014; 371(11):1067-1069.
5. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70(20):7992-8002.
6. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71 (18):6019-6029.
7. Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270-2282.
8. de Leeuw R, Berman-Booty LD, Schiewer MJ, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21(4):795-807.
9. Roberts J, Dhillon R, Dransfield DT, Mamlouk KK, Ferrante KJ. Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol. 2015;33(suppl 7):abstr 259.
10. Taplin ME, Montgomery RB, ARMOR2 Group. ARMOR2: galeterone in progressive CRPC patients who have failed oral therapy. J Clin Oncol. 2014;32 (suppl 4):abstr 71.
11. Lu J, Lonergan PE, Nacusi LP, et al. The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol. 2015;193(2):690-698.